Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine
Abstract Needle-free delivery of a six-plasmid HIV-1 DNA vaccine encoding EnvA, EnvB, EnvC, and subtype B Gag, Pol, and Nef underwent open-label evaluation in 15 subjects; 14 completed the 0, 1, 2 month vaccination schedule. T cell responses to HIV-specific peptide pools were detected by intracellul...
Gespeichert in:
| Veröffentlicht in: | Vaccine 2007-05, Vol.25 (20), p.4085-4092 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 4092 |
|---|---|
| container_issue | 20 |
| container_start_page | 4085 |
| container_title | Vaccine |
| container_volume | 25 |
| creator | Catanzaro, Andrew T Roederer, Mario Koup, Richard A Bailer, Robert T Enama, Mary E Nason, Martha C Martin, Julie E Rucker, Steve Andrews, Charla A Gomez, Phillip L Mascola, John R Nabel, Gary J Graham, Barney S |
| description | Abstract Needle-free delivery of a six-plasmid HIV-1 DNA vaccine encoding EnvA, EnvB, EnvC, and subtype B Gag, Pol, and Nef underwent open-label evaluation in 15 subjects; 14 completed the 0, 1, 2 month vaccination schedule. T cell responses to HIV-specific peptide pools were detected by intracellular cytokine staining of CD4+ [13/14 (93%)] and CD8+ [5/14 (36%)], and by ELISpot in 11/14 (79%). Ten of 14 (71%) had ELISA antibody responses to Env proteins. Compared to a four-plasmid product, Gag- and Nef-specific T cell responses were improved, while Env-specific responses were maintained. This candidate vaccine has now advanced to Phase II evaluation. |
| doi_str_mv | 10.1016/j.vaccine.2007.02.050 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70439247</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0264410X07001909</els_id><sourcerecordid>19740793</sourcerecordid><originalsourceid>FETCH-LOGICAL-c507t-6ed498155cbb90eb2035147555a28813fa8f702c6f60a643b1730e23f37074103</originalsourceid><addsrcrecordid>eNqFkk1v1DAQhi0EokvhJ4AsoXJLGNtxHF9AVQt0papFKiBuluNMhJd8LHayov8erzZopV56msszo3fmGUJeM8gZsPL9Jt9Z5_yAOQdQOfAcJDwhK1YpkXHJqqdkBbwssoLBzxPyIsYNAEjB9HNywpTQrGJyRe6-_rIR6Zq6zg_e2Y7iznaznfw40LGllkb_N9t2Nva-of3cTd51tkF6tf6RMXp5c06dHRrf2AnpkugledbaLuKrpZ6S758_fbu4yq5vv6wvzq8zJ0FNWYlNoVMI6epaA9YchGSFklJaXlVMtLZqFXBXtiXYshB1Sg3IRSsUqLSVOCXvDnO3YfwzY5xM76PDrrMDjnM0CgqheaEeBZlWBSgtEvj2AbgZ5zCkJUzKqaEqmKgSJQ-UC2OMAVuzDb634d4wMHs5ZmOWU5i9HAPcJDmp780yfa57bI5di40EnC2AjUlFG-zgfDxySa3mlU7cxwOH6bo7j8FE53Fw2PiAbjLN6B-N8uHBhP_-f-M9xuPWJqYGc7f_pP0jgQJgGrT4B0crwJQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1559084138</pqid></control><display><type>article</type><title>Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Catanzaro, Andrew T ; Roederer, Mario ; Koup, Richard A ; Bailer, Robert T ; Enama, Mary E ; Nason, Martha C ; Martin, Julie E ; Rucker, Steve ; Andrews, Charla A ; Gomez, Phillip L ; Mascola, John R ; Nabel, Gary J ; Graham, Barney S</creator><creatorcontrib>Catanzaro, Andrew T ; Roederer, Mario ; Koup, Richard A ; Bailer, Robert T ; Enama, Mary E ; Nason, Martha C ; Martin, Julie E ; Rucker, Steve ; Andrews, Charla A ; Gomez, Phillip L ; Mascola, John R ; Nabel, Gary J ; Graham, Barney S ; The VRC 007 Study Team ; VRC 007 Study Team</creatorcontrib><description>Abstract Needle-free delivery of a six-plasmid HIV-1 DNA vaccine encoding EnvA, EnvB, EnvC, and subtype B Gag, Pol, and Nef underwent open-label evaluation in 15 subjects; 14 completed the 0, 1, 2 month vaccination schedule. T cell responses to HIV-specific peptide pools were detected by intracellular cytokine staining of CD4+ [13/14 (93%)] and CD8+ [5/14 (36%)], and by ELISpot in 11/14 (79%). Ten of 14 (71%) had ELISA antibody responses to Env proteins. Compared to a four-plasmid product, Gag- and Nef-specific T cell responses were improved, while Env-specific responses were maintained. This candidate vaccine has now advanced to Phase II evaluation.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2007.02.050</identifier><identifier>PMID: 17391815</identifier><identifier>CODEN: VACCDE</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>Acquired immune deficiency syndrome ; Adolescent ; Adult ; AIDS ; AIDS Vaccines - administration & dosage ; AIDS Vaccines - adverse effects ; AIDS Vaccines - genetics ; AIDS Vaccines - immunology ; Allergy and Immunology ; Applied microbiology ; Biological and medical sciences ; CD4-Positive T-Lymphocytes - immunology ; CD8-Positive T-Lymphocytes - immunology ; Deoxyribonucleic acid ; DNA ; Envelope ; Female ; Fundamental and applied biological sciences. Psychology ; Gag ; Gene Products, env - immunology ; Gene Products, gag - immunology ; Gene Products, nef - immunology ; HIV ; HIV Antibodies - biosynthesis ; HIV Antibodies - immunology ; HIV Infections - immunology ; HIV Infections - prevention & control ; HIV Infections - virology ; HIV-1 - genetics ; HIV-1 - immunology ; Human immunodeficiency virus ; Human immunodeficiency virus 1 ; Human viral diseases ; Humans ; Immunity, Cellular - immunology ; Infectious diseases ; Laboratories ; Male ; Medical sciences ; Microbiology ; Miscellaneous ; Nef ; nef Gene Products, Human Immunodeficiency Virus ; Plasmids ; Plasmids - genetics ; Plasmids - immunology ; Pol ; Prevention ; Promoter ; T cell response ; Vaccines ; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) ; Vaccines, Combined - administration & dosage ; Vaccines, Combined - adverse effects ; Vaccines, Combined - genetics ; Vaccines, Combined - immunology ; Vaccines, DNA - administration & dosage ; Vaccines, DNA - adverse effects ; Vaccines, DNA - genetics ; Vaccines, DNA - immunology ; Viral diseases ; Viral diseases of the lymphoid tissue and the blood. Aids ; Virology</subject><ispartof>Vaccine, 2007-05, Vol.25 (20), p.4085-4092</ispartof><rights>2007</rights><rights>2007 INIST-CNRS</rights><rights>Copyright Elsevier Limited May 16, 2007</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c507t-6ed498155cbb90eb2035147555a28813fa8f702c6f60a643b1730e23f37074103</citedby><cites>FETCH-LOGICAL-c507t-6ed498155cbb90eb2035147555a28813fa8f702c6f60a643b1730e23f37074103</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0264410X07001909$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18739289$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17391815$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Catanzaro, Andrew T</creatorcontrib><creatorcontrib>Roederer, Mario</creatorcontrib><creatorcontrib>Koup, Richard A</creatorcontrib><creatorcontrib>Bailer, Robert T</creatorcontrib><creatorcontrib>Enama, Mary E</creatorcontrib><creatorcontrib>Nason, Martha C</creatorcontrib><creatorcontrib>Martin, Julie E</creatorcontrib><creatorcontrib>Rucker, Steve</creatorcontrib><creatorcontrib>Andrews, Charla A</creatorcontrib><creatorcontrib>Gomez, Phillip L</creatorcontrib><creatorcontrib>Mascola, John R</creatorcontrib><creatorcontrib>Nabel, Gary J</creatorcontrib><creatorcontrib>Graham, Barney S</creatorcontrib><creatorcontrib>The VRC 007 Study Team</creatorcontrib><creatorcontrib>VRC 007 Study Team</creatorcontrib><title>Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>Abstract Needle-free delivery of a six-plasmid HIV-1 DNA vaccine encoding EnvA, EnvB, EnvC, and subtype B Gag, Pol, and Nef underwent open-label evaluation in 15 subjects; 14 completed the 0, 1, 2 month vaccination schedule. T cell responses to HIV-specific peptide pools were detected by intracellular cytokine staining of CD4+ [13/14 (93%)] and CD8+ [5/14 (36%)], and by ELISpot in 11/14 (79%). Ten of 14 (71%) had ELISA antibody responses to Env proteins. Compared to a four-plasmid product, Gag- and Nef-specific T cell responses were improved, while Env-specific responses were maintained. This candidate vaccine has now advanced to Phase II evaluation.</description><subject>Acquired immune deficiency syndrome</subject><subject>Adolescent</subject><subject>Adult</subject><subject>AIDS</subject><subject>AIDS Vaccines - administration & dosage</subject><subject>AIDS Vaccines - adverse effects</subject><subject>AIDS Vaccines - genetics</subject><subject>AIDS Vaccines - immunology</subject><subject>Allergy and Immunology</subject><subject>Applied microbiology</subject><subject>Biological and medical sciences</subject><subject>CD4-Positive T-Lymphocytes - immunology</subject><subject>CD8-Positive T-Lymphocytes - immunology</subject><subject>Deoxyribonucleic acid</subject><subject>DNA</subject><subject>Envelope</subject><subject>Female</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Gag</subject><subject>Gene Products, env - immunology</subject><subject>Gene Products, gag - immunology</subject><subject>Gene Products, nef - immunology</subject><subject>HIV</subject><subject>HIV Antibodies - biosynthesis</subject><subject>HIV Antibodies - immunology</subject><subject>HIV Infections - immunology</subject><subject>HIV Infections - prevention & control</subject><subject>HIV Infections - virology</subject><subject>HIV-1 - genetics</subject><subject>HIV-1 - immunology</subject><subject>Human immunodeficiency virus</subject><subject>Human immunodeficiency virus 1</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Immunity, Cellular - immunology</subject><subject>Infectious diseases</subject><subject>Laboratories</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Microbiology</subject><subject>Miscellaneous</subject><subject>Nef</subject><subject>nef Gene Products, Human Immunodeficiency Virus</subject><subject>Plasmids</subject><subject>Plasmids - genetics</subject><subject>Plasmids - immunology</subject><subject>Pol</subject><subject>Prevention</subject><subject>Promoter</subject><subject>T cell response</subject><subject>Vaccines</subject><subject>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)</subject><subject>Vaccines, Combined - administration & dosage</subject><subject>Vaccines, Combined - adverse effects</subject><subject>Vaccines, Combined - genetics</subject><subject>Vaccines, Combined - immunology</subject><subject>Vaccines, DNA - administration & dosage</subject><subject>Vaccines, DNA - adverse effects</subject><subject>Vaccines, DNA - genetics</subject><subject>Vaccines, DNA - immunology</subject><subject>Viral diseases</subject><subject>Viral diseases of the lymphoid tissue and the blood. Aids</subject><subject>Virology</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkk1v1DAQhi0EokvhJ4AsoXJLGNtxHF9AVQt0papFKiBuluNMhJd8LHayov8erzZopV56msszo3fmGUJeM8gZsPL9Jt9Z5_yAOQdQOfAcJDwhK1YpkXHJqqdkBbwssoLBzxPyIsYNAEjB9HNywpTQrGJyRe6-_rIR6Zq6zg_e2Y7iznaznfw40LGllkb_N9t2Nva-of3cTd51tkF6tf6RMXp5c06dHRrf2AnpkugledbaLuKrpZ6S758_fbu4yq5vv6wvzq8zJ0FNWYlNoVMI6epaA9YchGSFklJaXlVMtLZqFXBXtiXYshB1Sg3IRSsUqLSVOCXvDnO3YfwzY5xM76PDrrMDjnM0CgqheaEeBZlWBSgtEvj2AbgZ5zCkJUzKqaEqmKgSJQ-UC2OMAVuzDb634d4wMHs5ZmOWU5i9HAPcJDmp780yfa57bI5di40EnC2AjUlFG-zgfDxySa3mlU7cxwOH6bo7j8FE53Fw2PiAbjLN6B-N8uHBhP_-f-M9xuPWJqYGc7f_pP0jgQJgGrT4B0crwJQ</recordid><startdate>20070516</startdate><enddate>20070516</enddate><creator>Catanzaro, Andrew T</creator><creator>Roederer, Mario</creator><creator>Koup, Richard A</creator><creator>Bailer, Robert T</creator><creator>Enama, Mary E</creator><creator>Nason, Martha C</creator><creator>Martin, Julie E</creator><creator>Rucker, Steve</creator><creator>Andrews, Charla A</creator><creator>Gomez, Phillip L</creator><creator>Mascola, John R</creator><creator>Nabel, Gary J</creator><creator>Graham, Barney S</creator><general>Elsevier Ltd</general><general>Elsevier</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7QO</scope><scope>7TM</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20070516</creationdate><title>Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine</title><author>Catanzaro, Andrew T ; Roederer, Mario ; Koup, Richard A ; Bailer, Robert T ; Enama, Mary E ; Nason, Martha C ; Martin, Julie E ; Rucker, Steve ; Andrews, Charla A ; Gomez, Phillip L ; Mascola, John R ; Nabel, Gary J ; Graham, Barney S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c507t-6ed498155cbb90eb2035147555a28813fa8f702c6f60a643b1730e23f37074103</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Acquired immune deficiency syndrome</topic><topic>Adolescent</topic><topic>Adult</topic><topic>AIDS</topic><topic>AIDS Vaccines - administration & dosage</topic><topic>AIDS Vaccines - adverse effects</topic><topic>AIDS Vaccines - genetics</topic><topic>AIDS Vaccines - immunology</topic><topic>Allergy and Immunology</topic><topic>Applied microbiology</topic><topic>Biological and medical sciences</topic><topic>CD4-Positive T-Lymphocytes - immunology</topic><topic>CD8-Positive T-Lymphocytes - immunology</topic><topic>Deoxyribonucleic acid</topic><topic>DNA</topic><topic>Envelope</topic><topic>Female</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Gag</topic><topic>Gene Products, env - immunology</topic><topic>Gene Products, gag - immunology</topic><topic>Gene Products, nef - immunology</topic><topic>HIV</topic><topic>HIV Antibodies - biosynthesis</topic><topic>HIV Antibodies - immunology</topic><topic>HIV Infections - immunology</topic><topic>HIV Infections - prevention & control</topic><topic>HIV Infections - virology</topic><topic>HIV-1 - genetics</topic><topic>HIV-1 - immunology</topic><topic>Human immunodeficiency virus</topic><topic>Human immunodeficiency virus 1</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Immunity, Cellular - immunology</topic><topic>Infectious diseases</topic><topic>Laboratories</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Microbiology</topic><topic>Miscellaneous</topic><topic>Nef</topic><topic>nef Gene Products, Human Immunodeficiency Virus</topic><topic>Plasmids</topic><topic>Plasmids - genetics</topic><topic>Plasmids - immunology</topic><topic>Pol</topic><topic>Prevention</topic><topic>Promoter</topic><topic>T cell response</topic><topic>Vaccines</topic><topic>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)</topic><topic>Vaccines, Combined - administration & dosage</topic><topic>Vaccines, Combined - adverse effects</topic><topic>Vaccines, Combined - genetics</topic><topic>Vaccines, Combined - immunology</topic><topic>Vaccines, DNA - administration & dosage</topic><topic>Vaccines, DNA - adverse effects</topic><topic>Vaccines, DNA - genetics</topic><topic>Vaccines, DNA - immunology</topic><topic>Viral diseases</topic><topic>Viral diseases of the lymphoid tissue and the blood. Aids</topic><topic>Virology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Catanzaro, Andrew T</creatorcontrib><creatorcontrib>Roederer, Mario</creatorcontrib><creatorcontrib>Koup, Richard A</creatorcontrib><creatorcontrib>Bailer, Robert T</creatorcontrib><creatorcontrib>Enama, Mary E</creatorcontrib><creatorcontrib>Nason, Martha C</creatorcontrib><creatorcontrib>Martin, Julie E</creatorcontrib><creatorcontrib>Rucker, Steve</creatorcontrib><creatorcontrib>Andrews, Charla A</creatorcontrib><creatorcontrib>Gomez, Phillip L</creatorcontrib><creatorcontrib>Mascola, John R</creatorcontrib><creatorcontrib>Nabel, Gary J</creatorcontrib><creatorcontrib>Graham, Barney S</creatorcontrib><creatorcontrib>The VRC 007 Study Team</creatorcontrib><creatorcontrib>VRC 007 Study Team</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>Biotechnology Research Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Catanzaro, Andrew T</au><au>Roederer, Mario</au><au>Koup, Richard A</au><au>Bailer, Robert T</au><au>Enama, Mary E</au><au>Nason, Martha C</au><au>Martin, Julie E</au><au>Rucker, Steve</au><au>Andrews, Charla A</au><au>Gomez, Phillip L</au><au>Mascola, John R</au><au>Nabel, Gary J</au><au>Graham, Barney S</au><aucorp>The VRC 007 Study Team</aucorp><aucorp>VRC 007 Study Team</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2007-05-16</date><risdate>2007</risdate><volume>25</volume><issue>20</issue><spage>4085</spage><epage>4092</epage><pages>4085-4092</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><coden>VACCDE</coden><abstract>Abstract Needle-free delivery of a six-plasmid HIV-1 DNA vaccine encoding EnvA, EnvB, EnvC, and subtype B Gag, Pol, and Nef underwent open-label evaluation in 15 subjects; 14 completed the 0, 1, 2 month vaccination schedule. T cell responses to HIV-specific peptide pools were detected by intracellular cytokine staining of CD4+ [13/14 (93%)] and CD8+ [5/14 (36%)], and by ELISpot in 11/14 (79%). Ten of 14 (71%) had ELISA antibody responses to Env proteins. Compared to a four-plasmid product, Gag- and Nef-specific T cell responses were improved, while Env-specific responses were maintained. This candidate vaccine has now advanced to Phase II evaluation.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>17391815</pmid><doi>10.1016/j.vaccine.2007.02.050</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 2007-05, Vol.25 (20), p.4085-4092 |
| issn | 0264-410X 1873-2518 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70439247 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Acquired immune deficiency syndrome Adolescent Adult AIDS AIDS Vaccines - administration & dosage AIDS Vaccines - adverse effects AIDS Vaccines - genetics AIDS Vaccines - immunology Allergy and Immunology Applied microbiology Biological and medical sciences CD4-Positive T-Lymphocytes - immunology CD8-Positive T-Lymphocytes - immunology Deoxyribonucleic acid DNA Envelope Female Fundamental and applied biological sciences. Psychology Gag Gene Products, env - immunology Gene Products, gag - immunology Gene Products, nef - immunology HIV HIV Antibodies - biosynthesis HIV Antibodies - immunology HIV Infections - immunology HIV Infections - prevention & control HIV Infections - virology HIV-1 - genetics HIV-1 - immunology Human immunodeficiency virus Human immunodeficiency virus 1 Human viral diseases Humans Immunity, Cellular - immunology Infectious diseases Laboratories Male Medical sciences Microbiology Miscellaneous Nef nef Gene Products, Human Immunodeficiency Virus Plasmids Plasmids - genetics Plasmids - immunology Pol Prevention Promoter T cell response Vaccines Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) Vaccines, Combined - administration & dosage Vaccines, Combined - adverse effects Vaccines, Combined - genetics Vaccines, Combined - immunology Vaccines, DNA - administration & dosage Vaccines, DNA - adverse effects Vaccines, DNA - genetics Vaccines, DNA - immunology Viral diseases Viral diseases of the lymphoid tissue and the blood. Aids Virology |
| title | Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T11%3A15%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Phase%20I%20clinical%20evaluation%20of%20a%20six-plasmid%20multiclade%20HIV-1%20DNA%20candidate%20vaccine&rft.jtitle=Vaccine&rft.au=Catanzaro,%20Andrew%20T&rft.aucorp=The%20VRC%20007%20Study%20Team&rft.date=2007-05-16&rft.volume=25&rft.issue=20&rft.spage=4085&rft.epage=4092&rft.pages=4085-4092&rft.issn=0264-410X&rft.eissn=1873-2518&rft.coden=VACCDE&rft_id=info:doi/10.1016/j.vaccine.2007.02.050&rft_dat=%3Cproquest_cross%3E19740793%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1559084138&rft_id=info:pmid/17391815&rft_els_id=1_s2_0_S0264410X07001909&rfr_iscdi=true |